<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00429104</url>
  </required_header>
  <id_info>
    <org_study_id>DM01-0100</org_study_id>
    <nct_id>NCT00429104</nct_id>
  </id_info>
  <brief_title>Herceptin and GM-CSF for Metastatic Breast Cancer</brief_title>
  <official_title>Phase II Study of GM-CSF to Overcome Herceptin-Resistant HER-2/Neu-Overexpressing Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:

        1. To determine the patient's tumor response rate that this protocol will produce.

        2. To determine the 1 year progression-free survival that this protocol will produce.

      Secondary Objective:

      1. To determine whether antibody-dependent cell-mediated cytotoxicity (ADCC) is the mechanism
      of overcoming Herceptin-resistance by use of Granulocyte-Macrophage Colony Stimulating Factor
      (GM-CSF).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GM-CSF stimulates the immune system and may increase the effectiveness of Herceptin.

      Before you can start treatment on this study, you will have what are called &quot;screening
      tests.&quot; These tests will help the doctor decide if you are eligible to take part in this
      study. You will have a complete medical history and physical exam. This includes blood tests
      (about 2 tea spoons), and x-rays. Women who are able to have children must have a negative
      blood or urine pregnancy test.

      If you are found to be eligible to take part in this study, you will receive trastuzumab
      through a vein (IV) every week until the disease gets worse. GM-CSF will be injected under
      the skin at least once a day until the white blood cell count is stable. GM-CSF will also
      continue during the course of study until the disease progresses.

      You will have further evaluation of your disease by computed tomography-CT scan, bone scan,
      chest X-ray, etc. at 2, 4, 6, 9, 12, 18, and 24 months after the start of treatment. You will
      have blood tests (about 2 tea spoons) at least twice a week until the appropriate dose of
      GM-CSF is found. The dose may increase or decrease depending on the blood test.

      You will have blood (about 2 tablespoons) drawn before treatment at the 2nd and 4th month,
      and if the disease gets worse.

      You will be removed from the study if the disease is progressing or severe side effects
      occur.

      This is an investigational study. The FDA has approved trastuzumab and GM-CSF, but their use
      in this study is experimental. A total of 36 patients will take part in this study. All will
      be enrolled at UT MD Anderson Cancer Center.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Tumor Response (Stable Disease)</measure>
    <time_frame>2 months</time_frame>
    <description>Number of participants with response defined as stable disease or better using Response Evaluation Criteria In Solid Tumors (RECIST) at the month 2 evaluation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Stable Disease</measure>
    <time_frame>6 Years</time_frame>
    <description>Stable disease is measured from the start of the treatment until the RECIST criteria for disease progression is met.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>HER2+ Metastatic Breast Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Herceptin 4 mg/kg IV Over 90 Minutes + GM-CSF 250 mcg/m^2 subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin</intervention_name>
    <description>4 mg/kg IV Over 90 Minutes</description>
    <arm_group_label>HER2+ Metastatic Breast Cancer</arm_group_label>
    <other_name>Trastuzumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GM-CSF</intervention_name>
    <description>250 mcg/m^2 Subcutaneously</description>
    <arm_group_label>HER2+ Metastatic Breast Cancer</arm_group_label>
    <other_name>Sargramostim</other_name>
    <other_name>Leukine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histological confirmation of invasive carcinoma of the breast.

          2. HER-2/neu overexpression: 3+ by immunohistochemical staining or Fluorescence in situ
             hybridization (FISH) (+).

          3. Stage IV breast cancer with measurable disease.

          4. Patient receiving progressive disease after Herceptin plus chemotherapy or Herceptin
             alone. No more than two Herceptin containing regimens.

          5. Zubrod performance status 0 or 1.

          6. Adequate hematological parameters (White Blood cells-WBC &gt; 3,000/mm3, platelet count &gt;
             100,000/mm3), adequate renal function (serum creatinine &lt; 2.0 mg/dl), adequate liver
             function (total bilirubin, aspartate aminotransferase (AST or SGOT) or alanine
             aminotransferase (ALT or SGPT) &lt; 3 x normal).

        Exclusion Criteria:

          1. Active Brain metastasis.

          2. No measurable disease at the time of registration (e.g. bone only, leptomeningeal
             disease alone or pleural effusion alone).

          3. More than 2 Herceptin containing regimens in metastatic breast cancer.

          4. Known history of HIV positive.

          5. Chronic active hepatitis or cirrhosis.

          6. Symptomatic pulmonary disease.

          7. Use of steroid of non-steroidal anti-inflammatory analgesic or Cox-2 inhibitor 1 week
             prior to registration.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naoto Ueno, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.T.M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>The University of Texas M.D.Anderson Cancer Center</description>
  </link>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2007</study_first_submitted>
  <study_first_submitted_qc>January 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2007</study_first_posted>
  <results_first_submitted>March 25, 2011</results_first_submitted>
  <results_first_submitted_qc>March 25, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 15, 2011</results_first_posted>
  <last_update_submitted>December 4, 2012</last_update_submitted>
  <last_update_submitted_qc>December 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Carcinoma of the Breast</keyword>
  <keyword>HER-2/neu Overexpression</keyword>
  <keyword>Herceptin</keyword>
  <keyword>Trastuzumab</keyword>
  <keyword>GM-CSF</keyword>
  <keyword>Sargramostim</keyword>
  <keyword>Leukine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period of November 2002 to April 2007, all recruited at University of Texas MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>HER2+ Metastatic Breast Cancer</title>
          <description>Herceptin 4 mg/kg intravenous (IV) Over 90 Minutes + Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) 250 mcg/m^2 subcutaneously</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HER2+ Metastatic Breast Cancer</title>
          <description>Herceptin 4 mg/kg intravenous (IV) Over 90 Minutes + Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) 250 mcg/m^2 subcutaneously</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" lower_limit="27" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Tumor Response (Stable Disease)</title>
        <description>Number of participants with response defined as stable disease or better using Response Evaluation Criteria In Solid Tumors (RECIST) at the month 2 evaluation.</description>
        <time_frame>2 months</time_frame>
        <population>Analysis was per protocol, and of 18 enrolled, one participant was inevaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>HER2+ Metastatic Breast Cancer</title>
            <description>Herceptin 4 mg/kg intravenous (IV) Over 90 Minutes + Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) 250 mcg/m^2 subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Tumor Response (Stable Disease)</title>
          <description>Number of participants with response defined as stable disease or better using Response Evaluation Criteria In Solid Tumors (RECIST) at the month 2 evaluation.</description>
          <population>Analysis was per protocol, and of 18 enrolled, one participant was inevaluable.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Stable Disease</title>
        <description>Stable disease is measured from the start of the treatment until the RECIST criteria for disease progression is met.</description>
        <time_frame>6 Years</time_frame>
        <population>Analysis was per protocol, and of 18 enrolled, one participant was inevaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>HER2+ Metastatic Breast Cancer</title>
            <description>Herceptin 4 mg/kg intravenous (IV) Over 90 Minutes + Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) 250 mcg/m^2 subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Stable Disease</title>
          <description>Stable disease is measured from the start of the treatment until the RECIST criteria for disease progression is met.</description>
          <population>Analysis was per protocol, and of 18 enrolled, one participant was inevaluable.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" lower_limit="10" upper_limit="53.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years and 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>HER2+ Metastatic Breast Cancer</title>
          <description>Herceptin 4 mg/kg intravenous (IV) Over 90 Minutes + Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) 250 mcg/m^2 subcutaneously</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Red eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sore Mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Itchy hands/feet</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Numbness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Sore finger/toes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash at injection site</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Skin Rash</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Naoto Ueno, MD.PhD./Professor</name_or_title>
      <organization>University of Texas MD Anderson Cancer Center</organization>
      <phone>713-792-8754</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

